Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101 by Braunstein, Marc J. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2011, Article ID 232037, 11 pages
doi:10.1155/2011/232037
Research Article
AntimyelomaEffects of the Heat Shock Protein 70 Molecular
Chaperone Inhibitor MAL3-101
Marc J. Braunstein,1 SadeaquaS. Scott,1 CraigM.Scott,2,3 Shannon Behrman,4
Peter Walter,4 Peter Wipf,5 Jeremy D. Coplan,1 WilliamChrico,1 DanielleJoseph,1
Jeffrey L.Brodsky,2 andOlcay Batuman1
1Division of Hematology/Oncology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
2Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
3Department of Biology, Clarion University, Clarion, PA 16214, USA
4Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco,
CA 94158, USA
5Department of Chemistry and Center for Chemical Methodologies and Library Development, University of Pittsburgh,
Pittsburgh, PA 15260, USA
Correspondence should be addressed to Olcay Batuman, obatuman@downstate.edu
Received 21 May 2011; Accepted 18 July 2011
Academic Editor: Edward A. Copelan
Copyright © 2011 Marc J. Braunstein et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, primarily due to the
treatment-refractory/resistant nature of the disease. A rational approach to this compelling challenge is to develop new drugs
that act synergistically with existing eﬀective agents. This approach will reduce drug concentrations, avoid treatment resistance,
and also improve treatment eﬀectiveness by targeting new and nonredundant pathways in MM. Toward this goal, we examined
the antimyeloma eﬀects of MAL3-101, a member of a new class of non-ATP-site inhibitors of the heat shock protein (Hsp) 70
molecular chaperone. We discovered that MAL3-101 exhibited antimyeloma eﬀects on MM cell lines in vitro and in vivo in a
xenograft plasmacytoma model, as well as on primary tumor cells and bone marrow endothelial cells from myeloma patients. In
combination with a proteasome inhibitor, MAL3-101 signiﬁcantly potentiated the in vitro and in vivo antimyeloma eﬀects. These
data support a preclinical rationale for small molecule inhibition of Hsp70 function, either alone or in combination with other
agents, as an eﬀective therapeutic strategy for MM.
1.Introduction
This study explored the cytotoxic eﬀects of MAL3-101,
a recently developed inhibitor of Hsp70 [1], on multiple
myeloma (MM) tumor growth. MM is a bone marrow (BM)
neoplasm of plasma cells and remains incurable [2]. Despite
signiﬁcant improvements in patient outcomes as a result of
high-dose chemotherapy with stem cell rescue, and novel
therapies with bortezomib, thalidomide, and lenalidomide
[3, 4], disease progression in MM leads to mortality resulting
from accumulating genetic mutations, prolonged tumor sur-
vival, and treatment resistance [5, 6]. Equally important in
MM pathogenesis and progression are the tumor enhancing
eﬀects of the BM microenvironment [7, 8], particularly
the increased neovascularization of the MM niche [9]b y
endothelial progenitor cells (EPCs) [10]. However, both
the tumor and microenvironment in MM are signiﬁcantly
aﬀected by proteasome inhibition via interruption of cell
survivalpathways[8,11–13].Thepotentantimyelomaeﬀects
of bortezomib (PS-341; Velcade), a ﬁrst-in-class selective
inhibitor of the 26S proteasome, are largely due to a
cellular stress response characterized by transcription of
proteasome subunits and molecular chaperones of the heat
shock protein family which include Hsp90 and Hsp70, and
their downstream regulators of tumor growth [8, 12, 14–20].
Thus, blockade of molecular chaperones is currently being2 Journal of Oncology
explored in preclinical studies and clinical trials for their
antimyeloma eﬀects, either synergistic with bortezomib or in
combination with other agents [4, 21, 22].
MAL3-101 inhibits the ability of Hsp40 cochaperones to
stimulate Hsp70 ATPase activity and thereby compromises
essential Hsp70 cellular functions [1, 23]. Our rationale for
studying the antimyeloma eﬀects of MAL3-101 was fourfold.
First, in plasma cells, the Hsp70 homolog in the endoplasmic
reticulum (ER), BiP, enhances the folding and secretion
of normal and misassembled immunoglobulins (IGs) and
prevents their accumulation [24]. Second, Hsp70 expression
is upregulated in MM cells [25, 26], and in treatment-
resistant MM cell lines [26], and especially after exposure to
clinicallyeﬀectiveantimyelomadrugsthatinhibitothercom-
ponentsoftheproteinqualitycontrolmachinery[27].Third,
Hsp70 gene expression and overexpression are associated
with human cancers [28–32]. Fourth, inhibition of Hsp70
in cancer cells triggers tumor-speciﬁc apoptosis and cell
death by inhibiting lysosomal membrane permeabilization,
a hallmark of stress-induced cell death [33, 34] The latter
mechanism was suggested by stabilization of lysosomes via
Hsp 70 binding to an endolysosomal anionic phospholipid
bis(monoacylglycero)phosphate (BMP), an essential cofac-
tor for lysosomal membrane sphingomyelin metabolism
[34].
Hsp70 gene and protein expression are upregulated in
MM cells after exposure to bortezomib as well as after appli-
cation of 17-allylamino-17-demethoxygeldanamycin (17-
AAG), which inhibits Hsp90 chaperones [11, 15, 16, 18, 25,
35]. Notably, Hsp70 acts at several nodes in the apoptotic
pathway [16, 29, 36], and thus its inhibition may overcome
the diﬀerential responsiveness to bortezomib as well as the
side eﬀects encountered in its use against MM [20, 22, 37].
Inturn,inhibitionofHsp72bysmallmoleculeinhibitorswas
shown to potentiate the in vitro apoptotic eﬀects of 17-AAG
on MM tumor cell lines [16, 21]. Thus, we reasoned that
MAL3-101 might act synergistically and potentiate in vitro
andinvivotheantimyelomaeﬀectsofproteasomeandHsp90
inhibitors.
In accordance with our premise, we discovered that
MAL3-101 exhibits potent inhibitory eﬀects on proliferation
and survival of MM cells, including primary tumor cells and
EPCs obtained from MM patients. MAL3-101-induced inhi-
bition of MM cell growth was characterized by an arrest of
cellcycleprogressionandactivationoftheintrinsicapoptotic
pathway in these cells. Moreover, strong synergy was found
in the in vitro cytotoxic eﬀects of MAL3-101 with inhibitors
of the proteasome and Hsp90. The synergy between MAL3-
101 and proteasome inhibition on MM cell growth was then
studied in vivo using the xenograft plasmacytoma mouse
model [38]. The in vivo study reproduced the inhibition of
tumor cell growth found in vitro. These data suggest that
by targeting Hsp70 activity in the tumor and its vascular
microenvironment, and by allowing a dose reduction of syn-
ergistic agents without compromising eﬀectiveness, Hsp70
inhibition could improve existing strategies by adding to the
arsenal of agents that combat MM and prolong survival by
circumventing treatment resistance.
2.MaterialsandMethods
2.1. Reagents and Cell Cultures. MAL3-101 and MAL3-51
(seeFigureS1intheSupplementarymaterialavailableonline
at doi: 10.1155/2011/232037), the proteasome inhibitors
MG-132 (A.G. Scientiﬁc, San Diego, Calif) and bortezomib
(PS-341, LC Labs, Woburn, Mass), and the Hsp90 inhibitor
17-AAG (Calbiochem/EMD Biosciences, San Diego, Calif)
were dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich,
S t .L o u i s ,M o )a n ds t o r e da t−20◦C. Control cells received
vehicle alone (0.03% DMSO). The MM cell lines examined
were NCI H929, RPMI-8226, and U266 (ATCC, Manassas,
Va). Normal peripheral blood mononuclear cells (PBMCs)
and bone marrow (BM) cells were obtained from StemCell
Technologies (Vancouver, Canada). Primary MM cells and
EPCs were from BM aspirates of newly diagnosed patients
following informed consent. MM cells were enriched to
>95% CD138+ cells by positive selection using anti-CD138
MACS Microbeads according to the manufacturer’s instruc-
tions (Miltenyi, San Diego, Calif). EPCs were derived from
BM aspirates of newly diagnosed patients, maintained in
EndoCultmedium(StemCellTechnologies),andusedatﬁrst
passage as previously described [39, 40]. Cell lines, PBMCs,
and BM cells were maintained in RPMI-1640 supplemented
with 10% heat-inactivated fetal calf serum as previously
described [39, 40].
2.2. Cytotoxicity Assays. Cells (1 × 105) were plated in 96-
well microtiter plates (Costar, Cambridge, Mass) in 100μL
of growth medium and exposed for the indicated periods to
the noted concentrations of compounds. Control cells were
cultured in the same volume of 0.03% DMSO. All studies
were performed in triplicate and repeated on at least three
independent occasions. Survival was measured by an MTS
assay (Promega, Madison, Wis) as per the manufacturer’s
directions. Cell viability was also measured by trypan blue
dye exclusion in identically plated cultures.
Apoptosisinductionincontrol(DMSO-treated)ordrug-
treated cells was determined using an Annexin-V-FLUOS
Staining Kit according to the manufacturer’s instructions
(Roche, Indianapolis, Ind). Brieﬂy, cells (1 × 105)w e r e
harvested at indicated time points after treatment, and
AnnexinV-ﬂuoresceinisothiocyanate(FITC)andpropidium
iodide (PI) were added to individual samples and incubated
for 30min in the dark. Fluorescence was analyzed by a
FACSort ﬂow cytometer (BD Biosciences, San Jose, Calif) by
acquiring 10,000 events per sample.
2.3. Cell Cycle Analysis. Cell cycle analysis of control
(DMSO-treated) and MAL3-101-treated NCI-H929 cells
(2 × 105) was assessed by PI staining and FACS analysis of
samples. Resulting DNA distributions were analyzed for the
proportions of cells in G0/G1 and G2/M phases of the cell
cycle after subtractive gating of cell doublets and debris, as
previously described [41].
2.4. Western Blotting. Whole-cell lysates were prepared using
the Mammalian Cell Lysis Kit (Sigma-Aldrich) and ana-
lyzed by Western blot analysis. Equal amounts of proteinJournal of Oncology 3
were separated by SDS-PAGE and electrotransferred onto
a nylon membrane. Primary antibodies to detect caspase-
3 (Cell Signaling Technology, Danvers, Mass), poly-ADP-
ribose polymerase (PARP; Abcam, Cambridge, Mass), and
β-actin (Sigma-Aldrich) were used along with a horseradish
peroxidase-conjugatedgoat-antimousepolyclonalsecondary
antibody (BD Biosciences, Franklin Lakes, NJ). Enhanced
chemiluminescence substrate (Pierce Biotechnology, Rock-
ford, Ill) was used for antibody detection.
2.5. Reverse-Transcription Polymerase Chain Reaction (RT-
PCR) Analysis of XBP1 mRNA Splicing. Unspliced (XBP-1u,
285bp) and spliced (XBP-1s, 259bp) XBP-1 mRNA levels
of treated NCI-H929 cells were determined by PCR ampli-
ﬁcation of total RNA that was reverse transcribed by Super-
Script Reverse Transcriptase (Invitrogen, Carlsbad, Calif).
PCR primers (5 -TTACGAGAGAAAACTCATGGC-3  and
5 GGGTCCAACTTGTCCAGAATGC-3 ), which ﬂank the
26-nt intron of XBP1 mRNA, were used for PCR ampliﬁca-
tion with Ex Taq polymerase (Takara Bio, Shiga, Japan).
2.6. Human Immunoglobulin Light-Chain Enzyme-Linked
Immunosorbent Assay (ELISA). Levels of secreted and intra-
cellular κ and λ light chains (LCs) were determined using
Human Kappa and Lambda (bound and free) ELISA
Quantitation Kits (Bethyl Laboratories, Montgomery, Tex)
according to the manufacturer’s instructions. Pellets and
supernatantswereobtainedfrom106 cellsculturedinserum-
free medium overnight. Total protein in whole-cell lysates
from cell pellets and supernatants was determined using
the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules,
Calif), and 500ng total protein was used in each ELISA. To
account for diﬀerences in secretion relative to synthesis of
LCs between MM cell lines, LC production was assessed as
the proportion of secreted versus intracellular LC levels.
2.7. Xenograft Plasmacytoma Murine Model. NOD/SCID/IL-
2R gamma null (NSG) mice (42–52 days old) were obtained
fromJacksonLaboratories(BarHarbor,Me)andmaintained
underpathogen-freeconditionsatSUNYDownstateMedical
Center animal resources facility. The study was conducted
according to protocol approved by the Institutional Animal
Care and Use Committee (IACUC) of Downstate Medical
Center. Mice were inoculated s.c. into the right ﬂank with
3 × 107 NCI-H929 cells in 100μL of RPMI 1640, together
with 100μL of Matrigel basement membrane matrix (BD
Biosciences, Bedford, Mass) as described by LeBlanc et al.
[38]. Mice were then divided into four treatment groups
containing 4 mice each receiving vehicle (DMSO and PBS),
or 1mg/kg PS-341 (Bortezomib), or 40mg/kg MAL3-101, or
1mg/kg PS-341 and 40mg/kg MAL3-101. All groups were
treated via i.p. injections twice weekly, at the same schedule.
Caliper measurements of the longest tumor diameters were
performed on the days of treatment to estimate the tumor
volume, using the following formula: 4π/3 × (width/2)
2 ×
(length/2), representing the three-dimensional volume of an
ellipse. Animals were sacriﬁced when their tumors reached
5.5cm or became necrotic; the earliest sacriﬁce was one of
the vehicle-treated animals on day 20 of treatment. Animal
studies were independently replicated, and data from all
experiments are shown.
2.8. Statistical Analysis. DMSO-treated cultures were com-
paredtodrug-treatedculturesbyStudent’st-testsorbyDun-
nett’s post hoc test following signiﬁcant repeated-measures
one-way analysis of variance. All tests were two tailed, and
statistical signiﬁcance was set at P ≤ .05. Isobologram
analyses were performed to derive combination index (CI)
values based upon the Chou-Talalay method using CalcuSyn
software (Biosoft, Ferguson, Mo and Cambridge, United
Kingdom) as described [14].
The in vivo component of the study was analyzed with
two approaches. First, the extent of plasmacytoma growth
was analyzed using a general linear model (GLM) with
days of tumor measurements as the repeated measure and
treatment condition (vehicle, MAL3-101, PS-341 or PS-341
plus MAL3-101 in combination) as the categorical variable.
In the GLM, we adjusted for the two experiments from
which the data had been collected (experiments 1 and 2). We
examined the statistical analysis for a repeated measure by
condition eﬀect to assess the diﬀerence between conditions
across the days of treatment. ANOVAs for condition eﬀects
were performed for each day followed by post hoc Tukey’s
honest signiﬁcant diﬀerence (HSD) testing. Second, using
the GLM analysis, we used the vehicle arm as a reference
point to calculate the mean percentage diﬀerence for each
treatment alone and the combination versus vehicle on
tumorgrowth.Resultswereadjustedforexperimentnumber.
Conditions were compared using post hoc testing with
Tukey’s HSD testing.
3. Results
3.1. MAL3-101 Suppresses Growth and Initiates Apoptosis
in Human MM Cells. To determine the eﬀect of MAL3-
101 on MM cell lines, NCI-H929, U266, and RPMI-8226
cells were cultured with increasing concentrations of MAL3-
101 and harvested at diﬀerent time points after treatment.
Control cells were treated with vehicle (DMSO). The highest
level of cytotoxicity, as assessed by an MTS assay, was
observed in NCI-H929 cells (Figure 1(a)); dose-response
studies at 40h exposure showed the IC50 to be 8.3μM
(Figure 1(b)). Exposure to MAL3-101 beyond 48h did not
result in an additional increase in cell death or apoptosis
(data not shown). In contrast, there was no response to 10
or 20μM MAL3-51 (Figure 1(b)), a substantially less potent
Hsp70 modulator [42]. These data strongly suggest that the
cytotoxic eﬀectofMAL3-101wasdirectlyrelatedtoitsability
to inhibit Hsp70 activity in NCI-H929 cells. A cytotoxic
eﬀect of MAL3-101 was also observed in the RPMI-8226 cell
line although to a lesser extent than observed on the NCI-
H929 cells (Figure 1(a)).
Because MAL3-101 initiates apoptosis through its ability
to arrest the cell cycle as well as by activating the cleavage
of caspase-3 and PARP in breast cancer cells [23], we next
examined these features in NCI-H929 cells. FACS analysis
showed that exposure to 10μM MAL3-101 produced a4 Journal of Oncology
time-dependent increase in apoptosis (Figure 2(a)). This
treatment also inhibited cell cycle progression, as indicated
by a nearly 3-fold increase in the sub-G0/G1 phase and a 2.5-
folddecreaseincellsintheG2/M phasewithin48hofculture
(Figure 2(b)). This result was supported by an immunoblot
analysis, which showed a time-dependent increase in the
cleavage of caspase-3 and PARP after exposure to MAL3-
101 (Figure 2(c)). Taken together, these results indicate that
MAL3-101 inhibits MM tumor cell growth and initiates an
apoptoticprogramwithsubstantiallygreatereﬃcacyinsome
cell lines than others.
3.2. Exposure to MAL3-101 Enhances the Antimyeloma Eﬀects
of MG-132. In MM cells, proteasome inhibition results
in the accumulation of misfolded and aggregation-prone
proteins, including unassembled IG heavy and light chains,
which can induce apoptosis [12, 17, 19, 43]. There-
fore, we asked whether MAL3-101 would potentiate the
antimyeloma eﬀect of proteasome inhibition. NCI-H929
cells were exposed to a range of MAL3-101 or MG-132
concentrations or to a range of concentrations of the two
agents in combination. We found that the IC50 for these
agents in combination decreased by up to three orders
of magnitude (0.008μM) when compared to single-agent
treatments with either MAL3-101 (IC50 8.3μM) or MG-
132 (IC50 1.7μM) (Figure 3(a) and Supplementary Table).
Notably, when examined alone, each compound was ineﬀec-
tive at the IC50 that was obtained when the compounds were
combined. In fact, the synergistic and cytotoxic actions of
MAL3-101 and MG-132 on NCI-H929 cells occurred over a
range of concentrations (0.01–0.1μM), as was conﬁrmed by
CI values of <1, which indicate strong synergy (Figure 3(b)).
As expected, a synergistic increase in apoptosis was also
observed in NCI-H929 cells exposed to a combination of the
two compounds (Figure S2).
Synergistic antimyeloma eﬀects of MAL3-101 and MG-
132 were also conﬁrmed in primary MM cells. As shown in
Figure 3(c), the viability of MM cells extracted from the BM
was reduced by 33% ± 8( P = 0.02) and 44% ± 10 (P =
0.07), respectively, by MAL3-101 and MG-132, and further
decreased by 75% ± 4( P = 0.001) when these agents were
combined. In addition to its eﬀects on tumor cells, com-
bined treatment with MAL3-101 and MG-132 also exerted
synergistic eﬀects on the MM microenvironment. As shown
in Figure 3(c) (white bars), the viability of EPCs was reduced
by 10%±14 (P = 0.7) and 16%±17 (P = 0.3) by MAL3-101
andMG-132,respectively,whiletheircombinationdecreased
EPC viability by 60% ± 7( P = 0.001). The speciﬁcity of
MAL3-101’s eﬀect on MM tumor and microenvironment
was indicated by a lack of cytotoxicity in normal control
BM, PBMC, and EPC populations (Figure 3(d)). These
results are consistent with a previously observed resistance
to proteasome inhibition in normal lymphocytes [44]a n d
furtherindicatethespeciﬁcityofactionofMAL3-101against
tumor cells in MM. Because the Hsp90 molecular chaperone
stabilizesoncoproteins,helpsmaintainMMcellhomeostasis,
and has synergy with bortezomib in vitro [15, 18], we next
assessed the eﬀect of MAL3-101 treatment when combined
with the antimyeloma Hsp90 inhibitor 17-AAG. When
NCI-H929 cells were simultaneously exposed to a single
concentration of MAL3-101 somewhat larger than its IC50
(10μM) and increasing concentrations of 17-AAG, we found
that the combination of MAL3-101 and 17-AAG decreased
the IC50 for 17-AAG from 0.4μMt o0 . 0 3μM (Figures 4(a)
and 4(b), and Supplementary Table). These results are
consistent with the prediction that the antimyeloma eﬀects
of Hsp90 inhibition, which causes upregulation of Hsp70
gene expression [15, 18], can be potentiated by simultaneous
inhibition of Hsp70 function.
To begin to examine how these compounds individually
and in combination impact the viability of NCI-H929 cells,
we asked whether the administration of the chemicals would
induce the unfolded protein response (UPR). Under condi-
tions of ER stress and UPR induction, the mRNA encoding
the X-box binding protein 1 (XBP-1) transcription factor
is spliced. This splicing event results in the translation of a
54-kDa XBP-1 spliced (XBP-1s) isoform rather than the 33-
kDaXBP-1unspliced(XBP-1u)isoform.Thesplicedisoform
is essential for plasma cell diﬀerentiation and possibly MM
progression[6,12],andXBP-1splicingrepresentsasensitive,
quantiﬁable readout for the UPR. At relatively early time
points, when UPR induction is maximal, no XBP-1 mRNA
splicing was observed after exposure of NCI-H929 cells to
MAL3-101, MG-132, or 17AAG at concentrations that had
resulted in synergistic cytotoxicity (Figure 5(a)). Consistent
with these results, we found that levels of the ER luminal BiP
chaperone, whose synthesis is enhanced by UPR activation,
did not change in NCI-H929 cells exposed to MAL3-101,
MG-132, and/or 17-AAG (data not shown). However, at
higher concentrations of MAL3-101 (30μM, ∼4-fold higher
than the IC50), a time-dependent increase in XBP-1 mRNA
splicing was noted (Figure 5(b)). UPR induction might
have resulted from a general Hsp70-dependent block in
translation, nascent protein folding, protein transit through
the secretory pathway, and/or transcription [12, 42, 45].
Strong experimental evidence indicates that the sensitiv-
ity of neoplastic MM cells to proteasome inhibition covaries
with monoclonal IG production [17, 19, 46, 47]. Therefore,
we measured IG production and traﬃcking in MAL3-101-
treated MM cell lines. When intracellular and secreted IGs
were quantiﬁed, we observed that the relative amount of
IG secretion was highest in NCI-H929 cells, which also
demonstrated the highest sensitivity to MAL3-101-induced
growth inhibition (Table 1). These data suggest that the
sensitivity of MM cells to Hsp70 inhibition arises from the
added cellular stress of producing and secreting monoclonal
IGs.
To determine the feasibility of quantifying the MAL3-
101-mediated inhibition of MM cell growth in response to
MAL3-101 in vivo, we used the subcutaneous NCI-H929
tumor (plasmacytoma) xenograft in NSG recipient mice
[38]. Treatments with vehicle (DMSO and PBS), or with
40mg/kg MAL3-101 and 1mg/kg PS-341 (bortezomib), or
with a combination of 40mg/kg MAL3-101 and 1mg/kg PS-
341 i.p., were started 24h after s.c. tumor cell injections.
Dose and schedule of drugs were supported by preliminaryJournal of Oncology 5
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Figure 1: MAL3-101 induces a graded cytotoxic eﬀect in multiple myeloma (MM) cell lines. (a) MM cell lines (1 × 105)w e r ee x p o s e dt o
10μM MAL3-101 for the indicated culture periods, and the fold change in percent viable cells in treated versus control cells was determined
by an MTS assay. (b) NCI-H929 cells were exposed to the indicated concentrations of MAL3-101 or MAL3-51 for 40h, and the percent
viability, as compared to control, DMSO-treated cells, was assessed by an MTS assay. Data are presented as means and SDs from three
independent experiments; ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001.
Table 1: MM cell line NCI-H929 is a high secretor of monoclonal IG. Multiple myeloma (MM) cell lines were grown at 1 × 106 cells/mL
for 16h, and 500ng total protein from cell lysates and 500ng from serum-free supernatants were used in ELISAs to determine intracellular
and secreted immunoglobulin (IG) light-chain (LC) levels, respectively. Relative LC secretion is shown as the proportion of secreted versus
intracellular LC levels. Data are presented as the mean ± SD from 3 independent experiments.
MM cell line Light chain (LC) produced Secreted LC (ng/106 cells) Intracellular LC (ng/106 cells) Relative LC secretion
(secreted/intracellular)
NCI-H929 κ 505 ± 22 93 ± 9.9 5.46 ± 0.4
U266 λ 639 ± 30 387 ± 32 1.66 ± 0.2
RPMI-8226 λ 56 ± 51 1271 ± 18 0.16 ± 0.1
observations of tumor growth in response to treatment with
MAL3-101 at an alternate dose and schedule (Figure S3).
Anoverallrepeatedmeasuresbytreatmentconditionwas
observed (F(15,50) = 4.89; P = 0.00001) as shown in
Figure 6(A). Compared to vehicle-treated controls, MAL3-
101 and PS-341 each delayed tumor growth over 20 days
from the initial treatment; however, in combination, MAL3-
101andPS-341hadagreatereﬀectthanthesingletreatments
by delaying tumor progression and reducing tumor size.
Signiﬁcant ANOVA eﬀects were noted for Days 6, 9, 13,
16, and 20 (Figure 6(A)). For days 6–20, tumor volume
was signiﬁcantly greater for vehicle than for combination
treatment with MAL3-101 and PS-341, and for days 13,
16, and 20, tumor volume was signiﬁcantly greater for
vehicle than PS-341 alone. No diﬀerences were noted for
vehicle versus MAL3-101 alone. In order to compare the
condition eﬀects on tumor progression, we computed the
mean percentage diﬀerence for each treatment versus vehicle
as shown in Figure 6(B). An overall condition eﬀect was
noted (F(2,7) = 10.25; P = 0.008). Analyses also showed
that combined treatment with PS-341 and MAL3-101 was
signiﬁcantly more eﬀective on percent tumor inhibition
in comparison to treatment with PS-341 or MAL3-101
individually (Tukey’s HSD test, P = 0.02; P = 0.008, resp.)
(Figure 6(B)). In summary, the in vivo data are in accordance
with our in vitro results and indicate that simultaneous
inhibition of the proteasome and Hsp70 by MAL3-101 has
a stable suppressive eﬀect on tumor growth detected as early
as day 6 in our MM model.
4. Discussion
The focus of this study was to measure the impact of
MAL3-101 on in vitro and in vivo growth of MM cells
and to predict the clinical eﬀectiveness of this compound
against MM. Our results provide evidence that MAL3-101
is cytotoxic to MM cells, and that synergistic eﬀects are
observed when this compound is used in combination with
Hsp90 or proteasome inhibitors.
In MM, the protein-folding machinery is overloaded due
to increased IG synthesis and secretion, and a signiﬁcant
population of the IGs may misfold; in fact, some MM cells
produce unassembled IG single chains. The concentration of
these proteins in the ER may be decreased by being retro-
translocated back to the cytoplasm, where they are degraded
by the proteasome, a process referred to as ER-associated
degradation (ERAD) [48, 49]. Since IGs fold in the ER and
traﬃc through the secretory pathway, proteasome inhibition
results in an increased load of misfolded proteins in the ER,6 Journal of Oncology
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Figure 2: MAL3-101 induces cell cycle arrest and caspase-mediated apoptosis in the multiple myeloma (MM) cell line NCI-H929. (a) MM
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of four experiments.Journal of Oncology 7
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Figure 3: MAL3-101 and MG-132 exhibit synergistic, cytotoxic eﬀects on multiple myeloma tumor cells and endothelial progenitor cells.
(a) NCI-H929 cells (1 × 105) were exposed to the indicated concentrations of MAL3-101, MG-132, or a combination of these agents for
40h, and survival was assessed by an MTS assay; representative data from one of seven independent experiments are shown; error bars
represent SDs from replicate data points. Apparent absence of error bars indicates minimal variance. (b) The fraction of nonviable cells
compared to control, DMSO-treated cells in this experiment was used for isobologram analysis. In brief, the cellular fraction aﬀected (Fa)
was calculated based on the indicated MTS assays using the following formula: Fa = 100 minus the percent of viable cells. Fa values at the
indicated drug concentrations were used by CalcuSyn to derive combination index (CI) values, where CI = 1 indicates additive eﬀects,
CI < 1 indicates synergy, and CI > 1 indicates antagonism [14]. (c) Bone-marrow-derived tumor cells (black bars) and conﬂuent endothelial
progenitor cells (EPCs) (white bars) from multiple myeloma patients were exposed to the indicated concentrations of MAL3-101, MG-132,
or their combination, and survival was assessed by an MTS assay. Dunnett’s test, after signiﬁcant one-way repeated-measures analyses of
variance (P = 0.004 and 0.002 for tumor cells and EPCs, resp.), compared control values to cell viability in cultures treated with MAL3-
101, MG-132, or MAL3-101 + MG-132 (∗P ≤ 0.05, ∗∗P ≤ 0.001). (d) Normal peripheral blood mononuclear cells (PBMCs, black bars),
bone marrow mononuclear cells (BMMCs, gray bars), and conﬂuent bone-marrow-derived EPCs (white bars) were exposed to the indicated
concentrations of MAL3-101, MG-132, or a combination of these agents, and survival was assessed by an MTS assay.
thus triggering apoptosis. Because Hsp70 homologs in the
ER and in the cytoplasm play critical roles in ERAD [28, 48,
49], it may not be surprising that we observed synergistic
cytotoxic eﬀects on MM cell survival when the proteasome
and Hsp70 were simultaneously inhibited. We also observed
synergisticcytotoxicityinMMcellsbyacombinedinhibition
ofHsp70andHsp90,furthersupportingthenotionthatMM
cells are susceptible to treatments that compromise protein
quality control.
The most MAL3-101-responsive cell line, NCI-H929, is
a high secretor of monoclonal IG [50] and is consistent
with other published data that IG load correlates with
sensitivity to inhibitors of the quality control machinery
[17, 43]. Even though the lack of UPR induction in MM
cells has been previously reported [12], we envisioned that
this response might be triggered when both Hsp70 and the
proteasome were inhibited since ERAD substrates should
accumulate. The lack of UPR induction by MAL3-101,
Hsp90, and proteasome inhibitors at the low concentrations
that induced synergistic apoptosis may be multifactorial:
While NCI-H929 cells synthesize and secrete large amounts
of IGs, they may be unable to induce a sustained UPR.
Alternatively, apoptosis may occur by pathways independent
of UPR activation, including autophagy [45]o ra g g r e s o m e8 Journal of Oncology
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Figure 4: MAL3-101 and 17-AAG exhibit synergistic, cytotoxic eﬀects on the MM cell line NCI-H929. (a) NCI-H929 cells (1 × 105)w e r e
exposed to 17-AAG alone or in combination with 10μM of MAL3-101 for 40h, and survival was assessed by an MTS assay. Representative
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isobologram analysis in CalcuSyn to derive combination index (CI) values, where CI < 1 indicates synergy [14].
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Figure 5: The unfolded protein response is not induced in NCI-H929 cells in response to chaperone and/or proteasome inhibition. RT-PCR
analysis was performed to assess XBP-1 mRNA splicing in NCI-H929 cells, and arrows on the right indicate the 285bp unspliced (XPB-
1u) and the 259bp spliced (XPB-1s) mRNA. (a) NCI-H929 cells were exposed for 4h to MAL3-101, MG-132, 17AAG, or the indicated
combination of the compounds, and total RNA was extracted for RT-PCR ampliﬁcation. NCI-H929 cells treated for 4h with 5μg/mL
tunicamycin (TM) as a positive control induced XBP-1 mRNA splicing. (b) NCI-H929 cells were exposed for 0, 24, 48, and 72h to 30μM
MAL3-101, and total mRNA was extracted for RT-PCR ampliﬁcation.
disposal [14]; therefore, it will be important to better
deﬁne at the molecular level the mechanisms that regulate
cell stress responses [51]. Further work is necessary to
establish whether MAL3-101 has eﬀects on pathways that are
upregulated in MM cells [14, 45]. Nevertheless, Davenport
and colleagues [15] showed that proteasome inhibition in
MM cell lines by bortezomib does not necessarily result in
the production of XBP1s, but ER stress and activation of the
intrinsic apoptotic pathway are evident. Moreover, 2h after
exposure to 17-AAG, there was a rapid initiation of the UPR,
which leads to ER stress and activation of intrinsic apoptotic
pathways. More recently, the same group discovered that the
17AAG-induced UPR was synergistically increased by Hsp72
inhibition in MM cell lines [21]. By analogy, we found that
the level of XBP1s increased after exposure to MAL3101
after48h.However, ateﬀectiveantimyelomaconcentrations,
we did not observe XBP1s when MAL3-101 and 17-AAG
were coadministered, unless much higher concentrations
and a prolonged incubation were used. We suggest that the
diﬀerent eﬀects observed may result from the nature of the
compounds that were employed to inhibit Hsp70, and/or
that the activities of unique Hsp70 family members may be
diﬀerentially aﬀected by these chemicals.
A critical result of our studies is the demonstration of
thesynergisticeﬀectsofHsp70andproteasomeinhibitionon
theMMmicroenvironment.WeandothershaveobservedIG
gene rearrangement in MM EPCs [40, 52]; therefore, protein
misfolding and the ensuing ER stress response may deter-
mine the susceptibility of tumor endothelial cells, in at least a
population of patients, to Hsp70 and proteasome inhibition.
This possibility is supported by a lack of sensitivity to MAL3-
101 in normal bone marrow, lymphocytes, and endothelial
cells, most of which do not produce IG. As a result, the
clinical application of MAL3-101 in MM may not only helpJournal of Oncology 9
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Figure 6: Eﬀect of MAL3-101 and PS-341 on myeloma cell growth in vivo. (A) shows repeated measures as condition eﬀect in NSG mice
which were inoculated subcutaneously in the right ﬂank with 3×107 NCI-H929 cells. Mice received 40mg/kg MAL3-101, 1mg/kg PS-341, a
combination of these agents, or the vehicle twice weekly i.p. (n = 16). Tumor volume assessments were performed on indicated days. Overall
repeated measures by treatment condition were observed (F(15,50) = 4.89; P = 0.00001), and MAL3-101 and PS-341 each delayed tumor
growth over 20 days from initial treatment; however, in combination, MAL3101 and PS-341 had a greater eﬀect than the single treatments
by delaying tumor progression and reducing tumor size. Vertical bars denote 0.95 conﬁdence interval. a–e refer to results of ANOVAs for
eﬀect of treatment by day on tumor inhibition. (a) Overall condition eﬀect on day 6: F(3,10) = 5.40; P = 0.018; Tukey HSD: vehicle >
MAL3-101 and PS-341 combination. (b) Overall condition eﬀect on day 9: F(3,10) = 5.25; P = 0.02; Tukey HSD: vehicle > MAL3-101
and PS-341 combination. (c) Overall condition eﬀect on day 13: F(3,10) = 10.57; P = 0.002; Tukey HSD: vehicle > MAL3-101 and PS-341
combination; vehicle > PS-341. (d) Overall condition eﬀect on day 16: F(3,10) = 8.16; P = 0.004; Tukey HSD: vehicle > MAL3-101 and PS-
341 combination; vehicle > PS-341. (e) Overall condition eﬀect on day 20: F(3,10) = 7.33; P = 0.01; Tukey HSD: vehicle > MAL3-101 and
PS-341 combination; vehicle > PS-341. (B) The bar graph shows the computed mean percentage diﬀerence for each treatment versus vehicle.
An overall condition eﬀect was noted (F(2,7) = 10.25; P = 0.008). Treatment with combination of PS-341 and MAL3-101 was signiﬁcantly
more eﬀective on percent tumor inhibition in comparison to PS-341 or MAL3-101 alone (Tukey’s HSD test, P = 0.02; P = 0.008, resp.),
although each individual treatment was not signiﬁcantly diﬀerent from each other. ∗indicates statistical signiﬁcance. Vertical bars denote
0.95 conﬁdence interval.
overcome drug resistance by potentiating the eﬀects of other
protein quality control inhibitors, but it may also limit MM
growth via inhibition of tumor angiogenesis.
The antimyeloma eﬀects of MAL3-101 were apparent
at concentrations similar to those used with 15-deoxys-
pergualin, a Hsp70 modulator with a KD for Hsp70 of
∼5μM. 15-Deoxyspergualin has proven successful in clin-
ical trials [53]; however, this compound is a nonspeciﬁc
chaperone inhibitor and may exhibit other oﬀ-pathway
eﬀects [54]. Our results are also in agreement with recent
data showing strong expression of Hsp70 expression in
MM cell lines at baseline and signiﬁcant upregulation after
extracellular matrix (ECM) adhesion [26]. In the same
report, it was also demonstrated that inhibition of Hsp70
gene expression induced a reduction in tumor cell adhesion
to ECM followed by an increase in apoptosis in MM
cells.
In summary, we suggest that MAL3-101, an Hsp70
modulator that speciﬁcally binds to Hsp70 and aﬀects its
interaction with cochaperones [1, 28, 55], may provide a
viable means to enhance the antimyeloma eﬀects of both
proteasome and Hsp90 inhibitors. Coadministration strate-
gies may reduce drug resistance in MM treatments and allow
thosepatientswhocurrentlycannottoleratebortezomib[13]
to beneﬁt from the drug because lower concentrations can
be used in conjunction with an MAL3-101-like molecule.
In addition to direct antitumor properties, MAL3-101 may
aﬀect the microenvironment by targeting the microvascu-
lature. Our experiments using a xenograft plasmacytoma
model show that tumor cell growth in vivo is also delayed
and reduced by MAL3-101, and that this inhibitory eﬀect
is synergistic for proteasome inhibition which was observed
within the ﬁrst week after combination treatment was
initiated. In this model, because we started treatment with
compounds within 24h of tumor initiation, the ﬁndings
may possibly be translated clinically to a restricted eﬀect
at earlier stages of the disease prior to extensive skeletal
involvement. It is also possible that combinations containing
higher doses of MAL3-101 with proteasome inhibition may
be required to control larger tumors and MM at its later
stages. The need to elucidate the pharmacokinetic properties
ofMAL3-101isunderscoredbytheseresultsforoptimization
of dose and frequency schedule of MAL3-101 exposure.
Particularly important will be the measurement of plasma
levels as well as rate and extent of clearance of the compound
when determining eﬀects versus toxicity. In the latter regard,
we do know that concentrations up to 160mg/kg i.p. have
been tolerated without toxicity (data not shown). The results
presented here strongly suggest that more detailed studies of
MAL3-101 pharmacokinetics are warranted.10 Journal of Oncology
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